翻译控制肿瘤蛋白在肿瘤靶向治疗中的分子作用机制及应用

doi:10.3760/cma.j.issn.1673-422X.2015.10.009

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (10): 753-755.doi: 10.3760/cma.j.issn.1673-422X.2015.10.009

翻译控制肿瘤蛋白在肿瘤靶向治疗中的分子作用机制及应用

韩玉婧,李亦兰,宁雪莲,孙慧莹,周春水

150081 哈尔滨医科大学基础医学院医学遗传学研究室

出版日期:2015-10-08 发布日期:2015-09-08
通讯作者: 周春水 E-mail:Zhoucs@ems.hrbmu.edu.cn
基金资助:
国家自然科学基金（81272582）

Molecular mechanism and application of translationally controlled tumor protein in tumor targeting therapy

Han Yujing, Li Yilan, Ning Xuelian, Sun Huiying, Zhou Chunshui.

Laboratory of Medical Genetics, School of Basic Medical Sciences of Harbin Medical University, Harbin 150081, China

Online:2015-10-08 Published:2015-09-08
Contact: Zhou Chunshui E-mail:Zhoucs@ems.hrbmu.edu.cn

摘要/Abstract

摘要： 翻译控制肿瘤蛋白（TCTP）是一种在多种生物中高度保守的小分子蛋白。TCTP在多种肿瘤细胞中高表达，已被证明参与调控细胞凋亡、DNA损伤与修复和耐药性形成等多种复杂功能。近年来，随着TCTP相关的分子作用机制不断被揭示，TCTP已成为肿瘤靶向治疗中的新型重要药物靶点。

关键词: DNA损伤, 抗药性, 肿瘤, 翻译控制肿瘤蛋白

Abstract: Translationally controlled tumor protein (TCTP) is a small protein highly conserved in a variety of eukaryotic species. TCTP is overexpressed in various tumor cells and has been implicated in the regulation of cellular processes including apoptosis, DNA repair and drug resistance. By reviewing the recent progress of TCTP research, TCTP is becoming an important regulator of DNA repair and a new molecular target for tumor therapy.

Key words: DNA damage, Drug resistance, neoplasm, Translationally controlled tumor protein

韩玉婧,李亦兰,宁雪莲,孙慧莹,周春水. 翻译控制肿瘤蛋白在肿瘤靶向治疗中的分子作用机制及应用[J]. 国际肿瘤学杂志, 2015, 42(10): 753-755.

Han Yujing, Li Yilan, Ning Xuelian, Sun Huiying, Zhou Chunshui.. Molecular mechanism and application of translationally controlled tumor protein in tumor targeting therapy[J]. Journal of International Oncology, 2015, 42(10): 753-755.

参考文献

［1］ Lu YJ, Lu G, Shi DZ, et al. Bioinformatic analysis for structure and function of TCTP from Spirometra mansoni［J］. Asian Pac J Trop Med, 2013, 6(9): 709-712. ［2］ NaganoIto M, Ichikawa S. Biological effects of Mammalian translationally controlled tumor protein (TCTP) on cell death, proliferation, and tumorigenesis［J］. Biochem Res Int, 2012, 2012: 204960. ［3］ Ma YP, Zhu WL. Cytoplasmic and nuclear localization of TCTP in normal and cancer cells［J］. Biochem Res Int, 2012, 2012: 871728. ［4］ Cucchi U, Gianellini LM, De Ponti A, et al. Phosphorylation of TCTP as a marker for pololike kinase1 activity in vivo［J］. Anticancer Res, 2010, 30(12): 4973-4985. ［5］ Yarm FR. Plk phosphorylation regulates the microtubulestabilizing protein TCTP［J］. Mol Cell Biol, 2002, 22(17): 6209-6221. ［6］ Zhang J, de Toledo SM, Pandey BN, et al. Role of the translationally controlled tumor protein in DNA damage sensing and repair［J］. Proc Natl Acad Sci USA, 2012, 109(16): E926-E933. ［7］ Hong ST, Choi KM. TCTP directly regulates ATM activity to control genome stability and organ development in drosophila melanogaster［J］. Nat Commun, 2013, 4: 2986. ［8］ van Soest RJ, de Morree ES, Shen L, et al. Initial biopsy gleason score as a predictive marker for survival benefit in patients with castrationresistant prostate cancer treated with docetaxel: data from the TAX327 study［J］. Eur Urol, 2013, 66(2):330-336. ［9］ Deng SS, Xing TY, Zhou HY, et al. Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human［J］. Genomics Proteomics Bioinformatics, 2006, 4(3): 165-172. ［10］ Kim JE, Koo KH, Kim YH, et al. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model［J］. Exp Mol Med, 2008, 40(6): 709-720. ［11］ Chung S, Kim M, Choi W, et al. Expression of translationally controlled tumor protein mRNA in human colon cancer［J］. Cancer Lett, 2000, 156(2): 185-190. ［12］ Zhu WL, Cheng HX, Han N, et al. Messenger RNA expression of translationally controlled tumor protein (TCTP) in liver regeneration and cancer［J］. Anticancer Res, 2008, 28(3A): 1575-1580. ［13］ Bull VH, Fargestad EM, Strozynski M, et al. Temporal proteome profiling of taxolinduced mitotic arrest and apoptosis［J］. Electrophoresis, 2010, 31(11): 1873-1885. ［14］ Ge F, Zhang L, Tao SC, et al. Quantitative proteomic analysis of tumor reversion in multiple myeloma cells［J］. J Proteome Res, 2011, 10(2): 845-855. ［15］ Lucibello M, Adanti S, Antelmi E, et al. PhosphoTCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells［J］. Oncotarget, 2015, 6(7): 5275-5291. ［16］ Miao X, Chen YB, Xu SL, et al. TCTP overexpression is associated with the development and progression of glioma［J］. Tumour Biol, 2013, 34(6): 3357-3361. ［17］ Li F, Zhang D, Fujise K. Characterization of fortilin, a novel antiapoptotic protein［J］. J Biol Chem, 2001, 276(50): 47542-47549. ［18］ Graidist P, Phongdara A, Fujise K. Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracilinduced cytotoxicity［J］. J Biol Chem, 2004, 279(39): 40868-40875. ［19］ Fujita T, Felix K, Pinkaew D, et al. Human fortilin is a molecular target of dihydroartemisinin［J］. FEBS Lett, 2008, 582(7): 1055-1060. ［20］ Liu LK, Wu HF, Guo ZR, et al. Targeted efficacy of dihydroartemisinin for translationally controlled protein expression in a lung cancer model［J］. Asian Pac J Cancer Prev, 2014, 15(6): 2511-2515. ［21］ Baylot V, Katsogiannou M, Andrieu C, et al. Targeting TCTP as a new therapeutic strategy in castrationresistant prostate cancer［J］. Mol Ther, 2012, 20(12): 2244-2256. ［22］ Ma Q, Geng Y, Xu W, et al. The role of translationally controlled tumor protein in tumor growth and metastasis of colon adenocarcinoma cells［J］. J Proteome Res, 2010, 9(1): 40-49. ［23］ Tuynder M, Fiucci G, Prieur S, et al. Translationally controlled tumor protein is a target of tumor reversion［J］. Proc Natl Acad Sci USA, 2004, 101(43): 15364-15369. ［24］ Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP［J］. Nat Med, 2011, 18(1): 91-99.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

翻译控制肿瘤蛋白在肿瘤靶向治疗中的分子作用机制及应用

Molecular mechanism and application of translationally controlled tumor protein in tumor targeting therapy

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价